aberrations and suit enough to tolerate FCR therapy, should still be very good candidates for the latter, With all the advantage being that this remedy is often completed in 6 months whilst ibrutinib has to be taken indefinitely.Richter transformation continues to be an ominous event for people with CLL, notably when it truly is clonally associated